Irvine Scientific receives CE Mark approval for human serum albumin
Protein supplement for gamete and embryo manipulation in assisted reproduction.
Irvine Scientific has announced the receipt of CE Mark approval for its human serum albumin solution (100 mg/mL) in normal saline (HSA). HSA is used in assisted reproductive procedures as a protein supplement for gamete and embryo manipulation.
Irvine Scientific’s HSA is manufactured according to cGMP guidelines and International Standards using only the highest quality, low endotoxin raw materials, to meet or exceed regulatory guidelines. Every lot undergoes extensive quality testing including sterility (USP <71>, CFR Title 21 part 610.12, Ph. Eur. 3.2 ), biocompatibility by Mouse Embryo Assay (MEA), to meet low endotoxin specifications (USP <85> and Ph. Eur. 2.6.14 Bacterial Endotoxins Test) as well as pH (USP <791> and Ph. Eur. 2.2.3) and Osmolality (USP <485> and Ph. Eur. 2.2.35).
“Irvine Scientific is committed to producing consistently high quality products to our customers, and to demonstrate that commitment by meeting the requirements of regulatory bodies worldwide,” said Timothy P. Mullane, Chief Operating Officer, Irvine Scientific. “We are pleased to be able to offer HSA with the CE Mark, especially for our European customers and network of distributors.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.